1. 124 AZACITIDINE VERSUS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS WITH NEWLY DIAGNOSED AML (>30% MARROW BLASTS) WITH MYELODYSPLASIA-RELATED CHANGES: SUBGROUP ANALYSIS OF THE AZA-AML-001 STUDY. (April 2015) Authors: Seymour, J.F.; Döhner, H.; Butrym, A.; Wierzbowska, A.; Selleslag, D.; Jang, J.H.; Cavenagh, J.D.; Kumar, R.; Schuh, A.C.; Candoni, A.; Récher, C.; Sandhu, I.; del Castillo, T. Bernal; Al-Ali, H.K.; Martinelli, G.; Falantes, J.; Nopenney, R.; Stone, R.M.; Minden, M.D.; McIntyre, H. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S63 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 15 HLA-MATCHED ALLOGENEIC STEM CELL TRANSPLANTATION IMPROVES OVERALL SURVIVAL OF HIGHER RISK MYELODYSPLASTIC SYNDROME. (April 2015) Authors: Robin, M.; Porcher, R.; Ades, L.; Raffoux, E.; Michallet, M.; François, S.; Cahn, J.Y.; Delmer, A.; Wattel, E.; Vigouroux, S.; Bay, J.O.; Cornillon, J.; Huynh, A.; Nguyen, S.; Rubio, M.T.; Vincent, L.; Maillard, N.; Charbonnier, A.; de Latour, R. Peffault; Oumedaly, R. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S6 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 50 BCL2L10-POSITIVE CELL (BPC) QUANTIFICATION IS A PREDICTIVE FACTOR OF SURVIVAL IN AZA-TREATED HIGHER RISK MDS (HR-MDS) AND AML. (April 2015) Authors: Cluzeau, T.; Vidal, V.; Ginet, C.; Karsenti, J.M.; Luciano, F.; Gastaud, L.; Garnier, G.; Braun, T.; Hirsch, P.; Raffoux, E.; Nloga, A.M.; Dombret, H.; Rorhlich, P.; Ades, L.; Chomienne, C.; Auberger, P.; Robert, G.; Fenaux, P. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S23 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 96 OVERALL SURVIVAL IN OLDER PATIENTS WITH NEWLY DIAGNOSED AML WITH >30% BONE MARROW BLASTS AND POOR-RISK CYTOGENETICS TREATED WITH AZACITIDINE: SUBANALYSIS OF THE AZA-AML-001 STUDY. (April 2015) Authors: Döhner, H.; Seymour, J.F.; Butrym, A.; Wierzbowska, A.; Selleslag, D.; Jang, J.H.; Cavenagh, J.D.; Kumar, R.; Schuh, A.C.; Candoni, A.; Récher, C.; Sandhu, I.; del Castillo, T. Bernal; Al-Ali, H.K.; Martinelli, G.; Falantes, J.; Nopenney, R.; Stone, R.M.; Minden, M.D.; McIntyre, H. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S48 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Azacitidine Prolongs Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) with Poor Prognostic Karyotypes. (April 2017) Authors: Döhner, H.; Vyas, P.; Seymour, J.F.; Santini, V.; Stone, R.M.; Minden, M.D.; Al-Ali, H.K.; del Castillo, T. Bernal; Morrill, J.; Songer, S.; Weaver, J.; Skikne, B.S.; Beach, C.L.; Dombret, H. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S70 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Azacitidine Versus Conventional Care Regimens (CCR) in Elderly Patients (≥75 Years) with Acute Myeloid Leukemia (AML) in the AZA-AML-001 Study. (April 2017) Authors: Seymour, J.F.; Buckstein, R.; Santini, V.; Döhner, H.; Stone, R.M.; Minden, M.D.; Kuo, C.Y.; Ben-Yehuda, D.; Bargay, J.; Songer, S.; Weaver, J.; Beach, C.L.; Dombret, H. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Clinical aspects and outcome of lymphoblastic leukemia/lymphoma with cutaneous involvement. (2019) Authors: Bontoux, C.; De Masson, A.; Boccara, O.; Bodemer, C.; Fraitag, S.; Balme, B.; Franck, N.; Carlotti, A.; Comoz, F.; Verneuil, L.; Brasme, J-F.; Duplan, M.; Croué, A.; Templier, I.; Beltraminelli, H.; Dereure, O.; Szablewski, V.; Thevenin, C.; Boulinguez, S.; Viraben, R. Journal: European journal of cancer Issue: Volume 119(2019)Supplement 1 Page Start: S10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemia. Issue 7 (7th June 2021) Authors: Fodil, S.; Raffoux, E.; Dumas, P. Y.; Desbrosses, Y.; Larosa, F.; Chantepie, S.; Larcher, M. V.; Mear, J. B.; Peterlin, P.; Hunault-Berger, M.; Hospital, M. A.; Morel, V.; Lucas, N.; Vidal, V.; Salanoubat, C.; Michel, J.; Mediavilla, C.; Ojeda-Uribe, M.; Alexis, M.; Frayfer, J. Journal: Leukemia & lymphoma Issue: Volume 62:Issue 7(2021) Page Start: 1756 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Impact of Gene Mutations on Survival with Azacitidine or Conventional Care Regimens (CCR) in Older Patients with Acute Myeloid Leukemia. (April 2017) Authors: Tang, L.; Dolnik, A.; MacBeth, K.J.; Dombret, H.; Seymour, J.F.; Minden, M.D.; Stone, R.M.; Beach, C.L.; Döhner, H.; Bullinger, L. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S69 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P374: BLINATUMOMAB AS CONSOLIDATION FOR ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA. A REAL-WORLD STUDY. (23rd June 2022) Authors: Urbino, I.; Lengline, E.; Cerrano, M.; Rabian, F.; Kim, R.; Sebert, M.; Itzykson, R.; Audisio, E.; Ades, L.; Dombret, H.; Raffoux, E.; Ferrero, D.; Clappier, E.; Boissel, N. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 274 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗